Literature DB >> 21051846

Effect of lyophilized lactobacilli and 0.03 mg estriol (Gynoflor®) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study.

G G G Donders1, B Van Bulck, P Van de Walle, R R Kaiser, G Pohlig, S Gonser, F Graf.   

Abstract

OBJECTIVES: To evaluate the efficacy of lyophilized lactobacilli in combination with 0.03 mg estriol when compared to metronidazole in the treatment of bacterial vaginal infections.
SETTING: Multicenter, randomized, single-blind, active-controlled pilot study in 3 independent gynecological practices in Belgium.
METHODS: Forty-six, 18- to 50-year-old premenopausal women with a disrupted vaginal flora due to a bacterial vaginal infection (bacterial vaginosis, aerobic vaginitis) were included, provided that fresh phase-contrast microscopy of the vaginal fluid showed lactobacillary flora grade 2B or 3. Patients were given a blinded box with either 12 vaginal tablets of Gynoflor® (study medication) or 6 vaginal suppositories containing 500 mg metronidazole (control medication). Eight efficacy variables were studied to assess the status of the vaginal flora at entry, 3-7 days (control 1), 4-6 (control 2) weeks and 4 months after the end of therapy.
RESULTS: At control 1, the combined variables equally improved in the lactobacilli group as in the metronidazole group. At control 2, the lactobacillus preparation showed slightly inferior results when compared to metronidazole. At 4 months, this analysis could not be performed due to low numbers, but analysis of recurrence rate and extra medication needed was not different between both groups.
CONCLUSION: Lyophilized lactobacilli in combination with low-dose estriol are equivalent to metronidazole in the short-term treatment of bacterial vaginal infections, but have less effect after 1 month. Further studies are required to evaluate the long-term efficacy of lactobacilli when applied repeatedly.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21051846     DOI: 10.1159/000314016

Source DB:  PubMed          Journal:  Gynecol Obstet Invest        ISSN: 0378-7346            Impact factor:   2.031


  14 in total

Review 1.  Exploring a road map to counter misconceptions about the cervicovaginal microbiome and disease.

Authors:  Jean M Macklaim; Craig R Cohen; Gilbert Donders; Gregory B Gloor; Janet E Hill; Groesbeck P Parham; Jacques Ravel; Gregory Spear; Janneke van de Wijgert; Gregor Reid
Journal:  Reprod Sci       Date:  2012-05-21       Impact factor: 3.060

Review 2.  Prevalence and treatment of aerobic vaginitis among non-pregnant women: evaluation of the evidence for an underestimated clinical entity.

Authors:  G S Tansarli; E K Kostaras; S Athanasiou; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-02-27       Impact factor: 3.267

3.  Selecting anti-microbial treatment of aerobic vaginitis.

Authors:  Gilbert G G Donders; Katerina Ruban; Gert Bellen
Journal:  Curr Infect Dis Rep       Date:  2015-05       Impact factor: 3.725

Review 4.  Deconstructing the genitourinary syndrome of menopause.

Authors:  Pedro Vieira-Baptista; Claudia Marchitelli; Hope K Haefner; Gilbert Donders; Faustino Pérez-López
Journal:  Int Urogynecol J       Date:  2017-03-14       Impact factor: 2.894

Review 5.  Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review.

Authors:  Cihat Unlü; Gilbert Donders
Journal:  J Turk Ger Gynecol Assoc       Date:  2011-12-01

6.  Antibacterial treatment of bacterial vaginosis: current and emerging therapies.

Authors:  Jean-Pierre Menard
Journal:  Int J Womens Health       Date:  2011-08-23

Review 7.  Individualized medicine and the microbiome in reproductive tract.

Authors:  Andrea G Braundmeier; Katherine M Lenz; Kristin S Inman; Nicholas Chia; Patricio Jeraldo; Marina R S Walther-António; Margret E Berg Miller; Fang Yang; Douglas J Creedon; Heidi Nelson; Bryan A White
Journal:  Front Physiol       Date:  2015-04-01       Impact factor: 4.566

8.  Isolation of Vaginal Lactobacilli and Characterization of Anti-Candida Activity.

Authors:  Carola Parolin; Antonella Marangoni; Luca Laghi; Claudio Foschi; Rogers Alberto Ñahui Palomino; Natalia Calonghi; Roberto Cevenini; Beatrice Vitali
Journal:  PLoS One       Date:  2015-06-22       Impact factor: 3.240

9.  Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study.

Authors:  Gilbert Donders; Patrick Neven; Maximilian Moegele; Anneleen Lintermans; Gert Bellen; Valdas Prasauskas; Philipp Grob; Olaf Ortmann; Stefan Buchholz
Journal:  Breast Cancer Res Treat       Date:  2014-04-10       Impact factor: 4.872

10.  The vaginal isolate Lactobacillus paracasei LPC-S01 (DSM 26760) is suitable for oral administration.

Authors:  Silvia Balzaretti; Valentina Taverniti; Greta Rondini; Giorgio Marcolegio; Mario Minuzzo; Maria C Remagni; Walter Fiore; Stefania Arioli; Simone Guglielmetti
Journal:  Front Microbiol       Date:  2015-09-15       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.